About us

We promise to open new horizons in the biomedical field.

Greetings from the CEO

Astrogen Ltd. is a clinical and research-oriented biotech company that develops innovative new drugs for treatment of intractable neurological diseases.

Without effective treatment, neurodevelopmental disorders and neurodegenerative diseases often require lifetime dependence on the family. Although the prevalence of neurological disorders and demand for treatment are both very high, fundamental treatments have not yet been developed worldwide. Our team comprising the best researchers of our country has established domestic and global R&D networks to conduct research in order to discover novels candidates and develop them to first-in-class drugs for management of difficult-to treat neurological diseases. Our non-clinical studies have shown that some of our active candidates currently under development are directly involved in the growth and development of neurons, protecting neurons from oxidative stress, improving mitochondrial function, and showing excellent effects on immune activity. In addition, we have evaluated the safety of the drug from drug interference, cytotoxicity, and genotoxicity studies, as well as in vivo  cognitive ability studies. Phase 1 and Phase 2 studies of AST-001 (development name) will be implemented by the first quarter of 2020,    and R&D of five pipeline candidates will be continued. We plan to expand the research to develop therapies for indications that have an unmet need.

Open innovation is being realized by Astrogen Ltd. affiliated research institutes such as Kyungpook National University Department of Life Science, Daegu Gyeongbuk Medical Innovation Foundation New Drug Development Support Center, Experimental Animal Center, New Drug Production Center, Korea Brain Research Institute, Korea Research Institute of Chemical Technology Drug Discovery Platform Technology Group, C&R Research, CC&I, J2H Biotech, and Kairos Bioconsulting. We promise to continue to expand the new drug pipeline for intractable neurological diseases to open new horizons in the biomedical field of drug discovery and development.

Thank you.

Astrogen Ltd. CEO Hwang Su-kyeong